關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

搜尋結果Search Result

符合「AML」新聞搜尋結果, 共 285 篇 ,以下為 1 - 24 篇 訂閱此列表,掌握最新動態
BitMEX achieves industry-leading low on-chain AML risk profile through strategic partnership with Chainalysis

BitMEX reports a 35% lower on-chain risk exposure than global averages, demonstrating its commitment to cutting-edge security and regulatory adherence. VICTORIA, Seychelles, Oct. 22, 2024 /PRNewswire/ -- BitMEX, the world's leading crypto derivatives exchange, has announced that it continues to maintain a low on-chain Anti-Money Laundering (AML) risk profile, successfully reducing its risk exposure from 1.7% in 2019 to just 0.2% in 2024. This 88% reduction in on-chain risk exposure over the past five years is a direct result of BitMEX's collaboration with Chainalysis, combined with substantial investments in compliance controls and advanced blockchain analytics. With its on-chain risk exposure 35% below the global average of 0.304%, BitMEX demonstrates its steadfast commitment to security and regulatory adherence, setting a new industry standard since 2019. As the industry navigates complex regulatory environments, BitMEX has turned compliance into an opportunity for leadership. Ongoing compliance efforts include bi-weekly updates to its Proof of Reserves and Liabilities, the use of geo-blocking technology to minimise sanctions-related risks, and regular external AML audits to ensure compliance accuracy. BitMEX also integrates advanced tools to monitor both on-chain and off-chain activity, reinforcing its comprehensive approach to risk management. Leveraging Chainalysis' cutting-edge blockchain analytics, BitMEX has implemented robust mechanisms to assess, monitor, and mitigate on-chain risks. On-chain risk exposure refers to the risks associated with the flow of digital assets, especially concerning their origin or destination, and BitMEX's proactive stance on mitigating these risks reinforces its leadership in safeguarding the crypto ecosystem. Stephan Lutz, CEO at BitMEX said, "As we continue to prioritise the safety of our users and create a secure trading environment, our collaboration with Chainalysis has allowed us to stay ahead of evolving compliance standards. By integrating advanced blockchain analytics into our comprehensive risk management strategy, we have not only reduced on-chain risk exposure but also strengthened the trust our users place in us. This partnership ensures that BitMEX leads the industry in both security and regulatory adherence, giving our traders confidence in the safety of their assets." The BitMEX compliance framework has evolved to reflect the highest standards in the industry. Central to this transformation is its risk-based approach to threshold tuning, which integrates insights from Chainalysis' detailed typologies and behavioural analytics. The platform's commitment to data integrity is evidenced by periodic testing and scenario selection based on the latest threat models, ensuring that its AML programme consistently meets regulatory expectations. "BitMEX has continuously taken an innovative and proactive approach towards enhancing their risk management strategy and prioritising consumer safety," said Diederik Van Wersch, Regional Director, ASEAN & Hong Kong, Chainalysis. "The team has always valued a strong collaboration when working with Chainalysis, and it's really impressive to see their investment in a skilled investigations and compliance team, and the adoption of advanced tools – which have yielded impressive results." BitMEX's efforts highlight its leadership in setting new benchmarks for transparency and regulatory adherence in the crypto space. With the continuous implementation of rigorous AML programmes and real-time monitoring systems, the platform is uniquely positioned to offer a secure and compliant environment for traders worldwide. More details on BitMEX's transformation of its risk profile is available via a Chainalysis case study here. About BitMEXBitMEX is the leading crypto derivatives exchange, providing professional crypto traders with a platform that caters to their needs with low latency, deep liquidity and unmatched reliability. Since our founding, no cryptocurrency has been lost through intrusion or hacking, allowing BitMEX users to trade safely in the knowledge that their funds are secure. So too that they have access to the products and tools they require to be profitable. BitMEX was also one of the first exchanges to publish their on-chain Proof of Reserves and Proof of Liabilities data. The exchange continues to publish this data twice a week – proving assurance that they safely store and segregate the funds they are entrusted with. For more information on BitMEX, please visit the BitMEX Blog or www.bitmex.com, and follow Discord, Telegram and Twitter. 

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 141 加入收藏 :
ISCA Partners COC to Launch New AML and CFT Initiatives to Enhance Charities Sector’s Financial Governance and Resilience

SINGAPORE - Media OutReach Newswire - 2 October 2024 - Minister for Culture, Community and Youth and Second Minister for Law Edwin Tong announced that the Institute of Singapore Chartered Accountants (ISCA) will partner the Office of the Commissioner of Charities (COC) to bolster the resilience of Singapore's charities sector through new anti-money laundering (AML) and countering the financing of terrorism (CFT) initiatives. He made this announcement at Charity Governance Conference 2024 today. ISCA partners COC to set up Charities AML/CFT Services Panel Recognising the pressing need for robust governance amid growing concerns over the vulnerabilities in fund-raising practices, ISCA and Office of COC will be rolling out subsidised services for charities in Singapore to help enhance their AML/CFT capabilities. This initiative will be led by a Charities AML/CFT Services Panel set up by ISCA, comprising accounting firms – Forbis Accounting Pte Ltd, InCorp Global and Unity Assurance Pte Ltd. Charities can approach the panel members for support in conducting due diligence checks, identify potential risks and provide interpretation of the screening results. They can also receive support in the drafting and implementation of AML/CFT policies and procedures at a low bono fee. ISCA's Community Accounting Programme ISCA is also spearheading digital transformation in the charities sector through its Community Accounting Programme, which was launched in October 2023 in partnership with the Office of COC and the National Council of Social Service. The programme is designed to accelerate the digital transformation of charities, particularly those with limited resources. It targets to support more than 50 charities and non-profit organisations by end-2024. A pilot programme was recently concluded in March 2024 with three charities which helped to digitalise their accounting and finance processes. For example, Fo Guang Shan (Singapore), a Buddhist organisation, benefitted from a transition to Xero, a cloud-based accounting solution, supported by Singapore Corporate Services Pte Ltd. The transition allowed the charities to automate manual tasks, retrieve supporting documents easily, as well as obtain up-to-date and accurate information for cashflow planning. More importantly, this has improved the charity's financial operations for better accountability and governance. These initiatives underscore ISCA's and Office of COC's commitment to advancing the charity sector, reinforcing public trust and promoting operational excellence. Professor Ang Hak Seng, Chairman of ISCA Charity Accounting Committee, said: "ISCA is committed to making an impact in the charities sector by working hand-in-hand with Office of COC. Together, we aim to strengthen charities' governance through initiatives like provision of AML risk consultancy, AML know your donor screening services, as well as our Community Accounting Programme. These initiatives help protect charities from money laundering threats and automation of robust finance processes to enhance transparency and accountability. As the national accountancy body, ISCA is happy to serve as a platform to enable ISCA members to contribute meaningfully and be able to make a lasting difference in the community." Commissioner of Charities, Mr Desmond Chin said: "We are pleased to partner ISCA to enhance the financial governance and resilience of our charity sector. The Charities AML/CFT Services Panel will provide charities with the tools and knowledge to strengthen their AML/CFT measures. We will continue working together with our partners to foster a culture of transparency and accountability to strengthen public trust in charities." Hashtag: #ISCA #Accountancy #Accounting #DifferenceMakers #AML #AntiMoneyLaundering #CFT #CounteringthefinancingofterrorismThe issuer is solely responsible for the content of this announcement.Institute of Singapore Chartered AccountantsThe Institute of Singapore Chartered Accountants (ISCA) is the national accountancy body of Singapore with over 36,000 ISCA members making their stride in businesses across industries in Singapore and around the world. ISCA members can be found in over 40 countries and members based out of Singapore are supported through 12 overseas chapters in 10 countries. Established in 1963, ISCA is an advocate of the interests of the profession. Complementing its global mindset with Asian insights, ISCA leverages its regional expertise, knowledge, and networks with diverse stakeholders to contribute towards the advancement of the accountancy profession. ISCA administers the Singapore Chartered Accountant Qualification programme and is the Designated Entity to confer the Chartered Accountant of Singapore – CA (Singapore) – designation. ISCA is a member of Chartered Accountants Worldwide, a global family that brings together the members of leading institutes to create a community of over 1.8 million Chartered Accountants and students in more than 190 countries. For more information, visit www.isca.org.sg.

文章來源 : Media OutReach Limited 發表時間 : 瀏覽次數 : 910 加入收藏 :
Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety

SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest results from a Phase Ib/II study of its Bcl-2 inhibitor lisaftoclax (APG-2575) in combination with azacitidine (AZA) in patients with treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML), in a poster presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community. Presenting clinical development progress at the ASCO Annual Meeting for the seventh consecutive year, Ascentage had four clinical studies of three of the company's proprietary drug candidates selected for presentations, including an oral report, at ASCO 2024. The data of lisaftoclax combined with AZA in elderly/unfit TN patients with AML who were intolerant of standard induction chemotherapies and patients with R/R AML showed excellent therapeutic potential and a favorable safety profile in terms of tumor lysis syndrome (TLS), low incidence of neutropenic fever, and low early mortality. "As a proprietary novel Bcl-2 inhibitor, lisaftoclax has shown treatment responses comparable to the approved Bcl-2 inhibitor and a better safety profile," said Prof. Jie Jin, a principal investigator of the study from the First Affiliated Hospital, Zhejiang University School of Medicine. "The improved safety offered by lisaftoclax means lower treatment-related mortality, fewer dose adjustments, and earlier start of sequential chemotherapies that should contribute to patients' long-term survival." "The introduction of Bcl-2 inhibitors represents a major breakthrough for the treatment of AML. However, the hematologic safety issues associated with the approved Bcl-2 inhibitor have limited the clinical adoption and the long-term efficacy," said Dr. Huafeng Wang, PhD, from the First Affiliated Hospital, Zhejiang University School of Medicine, and the presenter of the poster. "As a novel drug, lisaftoclax was frequently presented and attracted broad interest. When combined with chemotherapies, lisaftoclax showed a rate of hematologic adverse events that was lower than that of the approved Bcl-2 inhibitor. More importantly, its hematologic adverse events were relatively mild and easy to manage. Its hematologic toxicity-related serious adverse events such as neutropenic fever and 30-/60-day mortalities were very low. This suggests that lisaftoclax-associated hematologic toxicities are transient, less serious, easier to manage, and therefore would have less negative impact on sequential chemotherapies. Overall, lisaftoclax has already shown a highly favorable clinical potential." "These efficacy and safety data of lisaftoclax combined with AZA in patients with AML are very encouraging because they reaffirmed the drug's global best-in-class potential as a hopeful new treatment option for patients with AML, a hematologic malignancy commonly associated with a poor prognosis," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "A global registrational Phase III study of lisaftoclax in AML is already underway. Remaining committed to the mission of addressing unmet clinical needs in China and around the world, we will accelerate the clinical development of lisaftoclax and bring this novel therapeutic to the broad population of patients with AML as soon as possible." Highlights of these data presented at ASCO 2024 are as follows: Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia Abstract#: 6541 Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Date and Time: June 3, 2024, Monday, 9:00 AM – 12:00 PM (Central Time) First Author: Huafeng Wang, MD, PhD, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Highlights: Background and introduction: Early studies showed that lisaftoclax in combination with various agents can synergistically induce apoptosis in AML. This poster presents follow-up safety and efficacy data from a Phase Ib/II study of lisaftoclax combined with AZA in adults with AML. Patient enrollment and methods: This study enrolled elderly (≥75 years)/unfit TN patients with AML who were intolerant of standard induction chemotherapies and patients (≥18 years) with R/R AML. Lisaftoclax (400/600/800 mg) was administered orally once daily in 28-day cycles. In the first treatment cycle, a daily ramp up schedule was used to prevent TLS. AZA was administered once daily on D1-D7 at 75 mg/m2. As of January 25, 2024, 76 patients with AML were enrolled, including 37 patients with R/R AML and 39 elderly/unfit patients with TN AML who were intolerant of standard induction chemotherapies. The median (range) age was 66 (20-81) years. Efficacy results: In patients with R/R AML treated with lisaftoclax combined with AZA, the overall response rate ([ORR]=CR + CRi + morphologic leukemia-free state [MLFS] + PR) was 72.7%, and the composite complete remission rate (CRc = CR + CRi) was 45.5%. In the 600 mg cohort (n=30), the median duration of treatment was 3.8 months, the ORR was 76.7%, the CRc was 50.0%, the median time to CRc was 2.5 months, the median PFS was 10.2 months, and the median overall survival (OS) was 14.7 months. Among patients with TN AML treated with lisaftoclax combined with AZA, the ORR was 64.1%, and the CRc was 51.3%. In the 600 mg cohort (n=29), the median duration of treatment was 3.3 months, and the median time to CRc was 1.9 months. The median PFS and median OS were not reached. 600 mg lisaftoclax combined with AZA was established as the recommended Phase II dose (RP2D) Safety results: All patients treated with lisaftoclax combined with AZA reported treatment-emergent adverse events (TEAEs), with 89.5% experiencing grade 3/4 TEAEs and 43.4% experiencing serious adverse events (SAEs). Common Grade ≥ 3 TEAEs reported in ≥ 10% of patients included neutropenia (57.9%), thrombocytopenia (50.0%), anemia (27.6%), pneumonia (17.1%), and febrile neutropenia (10.5%). No TLS was reported. The 30-day mortality rate was 1.3%. Conclusions: These data support a promising role for the new Bcl-2 inhibitor lisaftoclax combined with AZA for the treatment of elderly/unfit TN patients with AML intolerant of standard induction chemotherapies and patients with R/R AML, especially given a potentially favorable safety profile in terms of TLS, the incidence of neutropenic fever, and low early mortality. A Phase III randomized, double-blind study is being conducted to determine whether lisaftoclax combined with AZA improves the survival of elderly/unfit TN patients with AML intolerant of standard induction chemotherapies. *Lisaftoclax is an investigational drug that has not been approved in any country and region. Appendix: The four clinical studies of Ascentage Pharma's three drug candidates, including lisaftoclax, presented at this year's ASCO Annual Meeting. Drug Candidates Abstract Title Abstract# Format Olverembatinib(HQP1351) Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) and paraganglioma. #11502 Oral Report Lisaftoclax (APG-2575) Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia. #6541 Poster Presentation Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM). #7078 Poster Presentation APG-2449 Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors. #3124 Poster Presentation   About Ascentage Pharma Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials, including 5 global registrational phase III studies, in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases. Olverembatinib, the company's core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company's first approved product in China, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company's investigational drug candidates. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients. Forward-Looking Statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 324 加入收藏 :
HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)

SAN DIEGO and WUHAN, China, April 23, 2024 /PRNewswire/ -- HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the Nature Portfolio online journal Scientific Reports. Narazaciclib (HX301 or ON123300) is a clinical stage small molecule investigational new drug jointly developed by HanxBio and its business partner OncoNova Therapeutics, Inc. (now Traws Pharma, Inc.). In this peer-reviewed article, the researchers from HanxBio described comprehensive pharmacology characterization of HX301 using a series of preclinical experimental AML models, including in vitro cell lines, and in vivo cell line-derived xenografts (CDXs) and patient-derived xenografts (PDXs). The report demonstrated the strong anti-leukemia activity of HX301 along with potential mechanism of actions (MOAs), including the inhibition of FLT3-ITD/TKD and potentially the inhibition of CSF1R, which is demonstrated in a robust experimental system beyond inv(16) subset for the first time. This report also studied the pharmacodynamics and pharmacokinetics of HX301, including the relationship between drug exposure and efficacy, which can be used to assist clinical dosage selection. Some of these works were conducted in collaboration with Crown Bioscience, Inc. and Kyinno Biotech, Ltd. Dr. Henry Li, President/Chief Scientific Officer of HanxBio and the corresponding author of this article, commended: "In-depth preclinical and translational research of HX301 helped us to identify clinical study indications as well as appropriate dose(s), thereby accelerating clinical development by increasing the probability of success. The results of this study will guide our clinical development strategies for HX301 for the treatment of AML." About HanxBio, Inc. HanxBio is a clinical stage biopharmaceutical company that develops innovative new medicines, focusing on research and development of precise innovative antibody, small molecule and antibody-drug conjugate (ADC) new drugs for the treatment of cancers and autoimmune diseases. The company's main scientific and managerial team have many years of experiences in the biopharmaceutical industries. HanxBio has built innovative drug product pipelines both in the clinical stages and preclinical stages. About HX301 It is a small molecule multi-kinase inhibitor jointly developed by HanxBio and its partner. It has completed phase I clinical trials in the United States and China, and it is currently been investigated in phase II clinical trials for various indications in China and the United States. Media Inquiries: HanxBio, Inc., Bruce Zhong: cheng.zhong@hanxbio.com

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 1445 加入收藏 :
Tookitaki 宣布將其 AML 套件更名為 FinCense 以體現該平台增強的功能

新加坡2024年2月5日 /美通社/ -- 防範金融犯罪領域的可靠領導者 Tookitaki 今日宣布將其旗艦反洗錢套件 (AMLS) 更名為 FinCense。該平台有無縫地緩解決欺詐和反洗錢風險功能。此項策略舉措將更好地體現其合規平台增強的功能。  欺詐和反洗錢挑戰的融合是合規格局發展新趨勢,促使金融機構尋求統一的解決方案。 目前,反欺詐和反洗錢團隊的營運處於孤立狀態。隨著成本的持續飆升,這時需要完整的解決方案統籌這兩個問題。 對於防範金融犯罪風險至關重要的跨境付款而言,這一點尤為重要。FinCense 以其 FRAML 解決方案彌合了欺詐和反洗錢之間的差距。 Tookitaki 創辦人兼行政總裁 Abhishek Chatterjee 先生強調了此次品牌重塑的重要性:「為什麼選擇 FinCense?因為它可以感知金融領域中存在的可疑情況。從 AMLS 到 FinCense 的過渡不僅是名稱的變更;它還標誌着市場上現有合規解決方案的關鍵進步。透過將欺詐和反洗錢合併到強大的單一解決方案中,我們讓金融機構能利用協同效應來提高偵測率、降低營運成本並即時防範欺詐。」 FinCense 憑藉擅長處理欺詐和反洗錢的複雜性的綜合平台,促進兩個領域之間的協作。 鑑於跨境付款獨特的複雜性及其對欺詐和反洗錢風險的敏感性,Tookitaki 精心設計 FinCense,為國內和跨境付款公司提供即時保護。FinCense 專為規模化而構建,能以 200 TPS 的高吞吐量處理數十億筆交易,從而即時防範欺詐。  關於 Tookitaki Tookitaki 在防範金融犯罪領域全球知名。其旗艦產品 FinCense 為亞洲、中東地區、非洲和美洲等 11 個國家/地區的全球領先金融機構提供服務,用以偵測和防範金融犯罪。FinCense 是業界最睿智的欺詐防範平台,為金融機構提供完善的反洗錢和反欺詐計劃,風險範圍的覆蓋無與倫比。其創新舉措的核心是反金融犯罪生態系統 (AFC),這是業界第一個由社群驅動的全球金融犯罪模式數碼儲存庫。FinCense 提供從入職訓練到持續盡職調查的點對點合規服務。FinCense 的現代資料工程堆棧可保證即時的回應能力和卓越的技術效能,從而確保更高的吞吐量、安全性和可用性。 聯絡方式:marketing@tookitaki.com

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 3935 加入收藏 :
Tookitaki Announces Rebranding of its AML Suite to FinCense to reflect the enhanced capabilities of the platform

SINGAPORE, Feb. 5, 2024 /PRNewswire/ -- Tookitaki, a trusted leader in the financial crime space, announced the rebranding of its flagship Anti Money Laundering Suite (AMLS) to FinCense. This strategic move is aimed at better representing the enhanced capabilities of its compliance platform, which now seamlessly addresses both fraud and AML risks. The convergence of fraud and AML challenges has reshaped the compliance landscape, leading financial institutions to seek a unified solution. Currently, operational silos divide anti-fraud and AML teams. As costs continue to soar, a complete solution to manage both is needed. This is especially critical in cross-border payments, where protection from Financial Crime risk is vital. FinCense bridges the gap between fraud and AML with its FRAML solution. Mr. Abhishek Chatterjee, Founder and CEO of Tookitaki, emphasised the significance of this rebranding, stating, "Why FinCense? Because it can sense finance aka suspicious patterns. Our transition from AMLS to FinCense signifies more than a name change; it marks a pivotal advancement in compliance solutions available in the market. By merging Fraud and AML prevention into a single, powerful solution, we enable financial institutions to capitalise on the synergy to improve detection rates, reduce operational costs and prevent fraud in real-time." FinCense fosters collaboration between fraud and AML prevention, with a comprehensive platform adept at handling both domains' complexities. Recognizing the unique intricacies of cross-border payments and their susceptibility to both Fraud and AML risks, FinCense has been carefully crafted to provide real-time protection for domestic and cross-border payment companies. FinCense is built for scale by processing billions of transactions with high throughput at 200 TPS for real-time fraud prevention.  About Tookitaki Tookitaki is a global name in the world of anti-financial crime. Its flagship product FinCense serves the world's leading financial institutions in 11 countries across Asia, Middle East, Africa, and Americas to detect and prevent financial crime. FinCense is the industry's most intelligent fraud prevention platform and provides financial institutions with unparalleled risk coverage for AML and Anti-Fraud programs. At the heart of its innovation is the Anti-Financial Crime Ecosystem (AFC), industry's first community-driven digital repository of global FinCrime patterns. FinCense offers end-to-end compliance, from onboarding to ongoing due diligence. FinCense's modern data engineering stack assures real-time responsiveness and superior technical performance, ensuring higher throughput, security and availability. Contact: marketing@tookitaki.com

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 472 加入收藏 :
2025 年 1 月 22 日 (星期三) 農曆十二月廿三日
首 頁 我的收藏 搜 尋 新聞發佈